Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Amplified”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02091960
What this trial is testing

Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Who this might be right for
HER2 AmplifiedAdvanced Breast CancerHuman Epidermal Growth Factor Receptor 2 (HER2)
Astellas Pharma Global Development, Inc. 103
Not applicableStudy completedNCT00097487
What this trial is testing

Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane

Who this might be right for
Breast CancerMetastases
Genentech, Inc. 1,000
Testing effectiveness (Phase 2)UnknownNCT05016544
What this trial is testing

Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 48
Testing effectiveness (Phase 2)Looking for participantsNCT07428044
What this trial is testing

Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerNon-small Cell Lung Cancer Stage IINon-Small Cell Lung Cancer Stage IIIA+1 more
Memorial Sloan Kettering Cancer Center 14
Testing effectiveness (Phase 2)Study completedNCT02005887
What this trial is testing

TRial on the Endocrine Activity of Neoadjuvant Degarelix

Who this might be right for
Breast Cancer Invasive Nos
ETOP IBCSG Partners Foundation 51
Testing effectiveness (Phase 2)Study completedNCT01975142
What this trial is testing

Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.

Who this might be right for
Metastatic Breast Cancer, HER2 Negative Primary Tumor
Institut Curie 155
Testing effectiveness (Phase 2)WithdrawnNCT01557764
What this trial is testing

Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Washington University School of Medicine
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Testing effectiveness (Phase 2)Looking for participantsNCT05751018
What this trial is testing

Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Peking Union Medical College Hospital 18
Testing effectiveness (Phase 2)Study completedNCT04466891
What this trial is testing

ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

Who this might be right for
HER2-amplified Biliary Tract Cancers
Jazz Pharmaceuticals 87
Testing effectiveness (Phase 2)Study completedNCT01614522
What this trial is testing

A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2

Who this might be right for
Stomach NeoplasmsCancer of StomachCancer of the Stomach+2 more
ASLAN Pharmaceuticals 24
Testing effectiveness (Phase 2)Ended earlyNCT03894007
What this trial is testing

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer

Who this might be right for
Early-stage Breast CancerHER2-positive Breast Cancer
Renske Altena 6
Testing effectiveness (Phase 2)Study completedNCT01828021
What this trial is testing

Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

Who this might be right for
Breast Cancer
MacroGenics 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT03820141
What this trial is testing

Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

Who this might be right for
Breast Cancer
The Methodist Hospital Research Institute 51
Large-scale testing (Phase 3)Looking for participantsNCT06380751
What this trial is testing

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
AstraZeneca 788
Early research (Phase 1)Looking for participantsNCT06364410
What this trial is testing

Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors

Who this might be right for
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+10 more
National Cancer Institute (NCI) 48
Early research (Phase 1)Study completedNCT03238196
What this trial is testing

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center 35
Testing effectiveness (Phase 2)WithdrawnNCT07570966
What this trial is testing

Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)UnknownNCT02884453
What this trial is testing

Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma

Who this might be right for
Gastrooesophageal Cancer
Royal Marsden NHS Foundation Trust 17
Testing effectiveness (Phase 2)Study completedNCT02675829
What this trial is testing

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Who this might be right for
Solid Tumor CancersLung CancerBladder Cancer+1 more
Memorial Sloan Kettering Cancer Center 131
Next Page